Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01503450
Other study ID # BE-171-OLAN-2006
Secondary ID
Status Completed
Phase Phase 1
First received January 2, 2012
Last updated January 4, 2012
Start date November 2006
Est. completion date December 2006

Study information

Verified date January 2012
Source Dr. Reddy's Laboratories Limited
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the single oral dose bioequivalence of olanzapine 5 mg OD tablets with Zyprexa Zydis 5 mg tablets under fed conditions and to monitor adverse events and ensure safety of subjects.


Description:

An open label, balanced, randomized, two treatment, two-sequence, two-period, single-dose, crossover comparative bioequivalence study of Olanzapine 5 mg OD Tablets, of Dr. Reddy's Laboratories Limited and Zyprexa Zydis 5 mg Tablets of Cardinal Health in healthy, human subjects under fed conditions.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date December 2006
Est. primary completion date December 2006
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Healthy human subjects within the age range of 18 to 45 years

- Non-smokers since at least six months

- Willingness to provide written informed consent to participate in the study

- Body-mass index of =18.5 kg/m2 and = 24.9 kg/m2, with body weight not less than 50 kg

- Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening

- Normal 12-lead ECG or one with abnormality considered to be clinically insignificant

- Normal chest X-ray PA view

- Comprehension of the nature and purpose of the study and compliance with the requirement of the protocol

- Female Subjects

- of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams. Jellies, diaphragm, intrauterine device (IUD), or abstinence, or

- postmenopausal for at least 1 year, or

- surgically sterile (bilateral tubal ligation. bilateral oophorectomy, or hysterectomy has been performed on the subject

Exclusion Criteria:

- Personal / family history of allergy or hypersensitivity to olanzapine or allied drugs

- Past history of anaphylaxis or angioedema

- Any major illness in the past three months or any clinically significant ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.

- Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver Function Test (LFT), Renal (kidney) Function Test (RFT), etc.

- Any cardiac, renal or liver impairment, any other organ or system impairment

- History of seizure or psychiatric disorders

- Presence of disease markers of HIV 1 and 2, and hepatitis Band C virus

- Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study [one drink is equal to one unit of alcohol [ one glass Wine, half plnt boor, and one measure (one ounce) of spirit).

- Consumption of xanthine containing derivatives (coffee, tea, cola drinks. chocolate) within 48 hours before check-in of each period

- Use of any recreational drug or a history of drug addiction

- Participation in any clinical trial within the past 3 months

- Inaccessibility of veins in left and right arm

- Donation of blood (one unit or 350 mL) within 3 months prior to receiving the first dose of study medication

- Receipt of any prescription drug therapy within four weeks or over-the-counter (OTC) drugs within two weeks prior to receiving the first dose of study medication or repeated use of drugs Within the last four weeks

- An unusual diet, for whatever reason e.g. low sodium diet, for two weeks prior to receiving any medication and through out subject's participation in the study

- Consumption of grapefruit- containing food or beverages within 7 days prior to receiving the first dose of study medication in both the periods

- Recent history of dehydration from diarrhea, vomiting or any other reason within a period of 24 hours prior to the study

- Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding

- Having an occupation or requirement of driving a vehicle or operate a complex machinery before 21 days of taking the drug in both periods

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Olanzapine OD Tablets 5 mg
Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited

Locations

Country Name City State
India Wellquest Clinical Research Mumbai Maharashtra

Sponsors (1)

Lead Sponsor Collaborator
Dr. Reddy's Laboratories Limited

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bioequivalence is based on Cmax and AUC parameters 2 months No
See also
  Status Clinical Trial Phase
Completed NCT01721187 - Satiety Effects on the Neural Valuation of Food N/A
Completed NCT01827878 - Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed Conditions Phase 1
Completed NCT01283932 - Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fed Condition Phase 1
Completed NCT01372306 - Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition Phase 1
Completed NCT03390881 - Use of Breath Acetone aa a Marker of Energy Balance N/A
Completed NCT01283867 - Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Non-Fasting Conditions Phase 1
Completed NCT01735383 - Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fed Condition Phase 1
Completed NCT01618760 - Bioequivalence Study of Risperidone Tablet 1 mg Under Fed Condition Phase 1
Completed NCT01578265 - Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fed Condition Phase 1
Recruiting NCT05837572 - Development of the Leeds Food Preference Questionnaire in Spanish N/A
Completed NCT01618825 - Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fed Condition Phase 1
Completed NCT01505998 - Bioequivalence Study of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg Capsules of Dr. Reddy's Under Fed Conditions Phase 1
Completed NCT01735344 - Bioequivalence Study of Lisinopril Tablets 40 mg Under Fed Condition Phase 1
Completed NCT01372358 - Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions Phase 1
Completed NCT01567501 - Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed Condition Phase 1
Completed NCT05995119 - Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers Early Phase 1
Completed NCT01314352 - Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions Phase 1
Completed NCT01744873 - Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fed Condition Phase 1
Completed NCT01503424 - Bioequivalence Study of Olanzapine Tablets, 5 mg Under Fed Study Phase 1
Completed NCT01884909 - Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fed Conditions Phase 1